Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-24
2006-01-24
Landsman, Robert S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S085400, C424S085500
Reexamination Certificate
active
06989364
ABSTRACT:
The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-γ). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.
REFERENCES:
patent: 4727138 (1988-02-01), Goeddel et al.
patent: 4762791 (1988-08-01), Goeddel et al.
patent: 4855238 (1989-08-01), Gray et al.
patent: 4925793 (1990-05-01), Goeddel et al.
patent: 4929544 (1990-05-01), Vold
patent: 5096705 (1992-03-01), Goeddel et al.
patent: 5151265 (1992-09-01), Hwang-Felgner et al.
patent: 5573762 (1996-11-01), Ferrara et al.
patent: 5574137 (1996-11-01), Gray et al.
patent: 5582824 (1996-12-01), Goeddel et al.
patent: 5595888 (1997-01-01), Gray et al.
patent: 5837241 (1998-11-01), Ferrara et al.
patent: 6207641 (2001-03-01), Torigoe et al.
patent: 790062 (1997-08-01), None
patent: WO 89/01341 (1989-02-01), None
patent: WO 90/03189 (1990-04-01), None
patent: WO 91/07984 (1991-06-01), None
Lam XM et al. Pharm. Res. 14(6):725-729, 1997.
Baehner, R.L., “Chronic Granulomatous Disease of Childhood: Clinical, Pathological, Biochemical, Molecular, and Genetic Aspects of the Disease”Pediatric Pathol.10:143-153 (1990).
Betocchi et al., “Effects of Diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy”Am. J. Cardiol.78:451-457 (1996).
Birks and Yacoub, “The role of nitric oxide and cytokines in heart failure”Coronary Artery Diseases8:389-402 (1997).
Bonow et al., “Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardimyopathy: short- and long-term effects”Circulation72:853-864 (1985).
Braunwald, E., “Pathophysiology of Heart Failure”Heart Disease, A Textbook of Cardiovascular Medicine,Third edition, W. B. Saunders Company pps. 426-448 (1988).
Caspari et al., “Collagen in the normal and hypertrophied human ventricle”Cardiovasc. Res.11: 554-558 (1977).
Chien et al., “Regulation of Cardiac Gene Expression During Myocardial Growth and Hypertrophy: Molecular Studies of an Adaptive Physiologic Response”FASEB J.5:3037-3046 (1991).
Chien et al., “Transcriptional Regulation During Cardiac Growth and Development”Annu. Rev. Physiol.55:77-95 (1993).
De Maeyer, E., “The Presence and Possible Pathogenic Role of Interferons in Disease”Interferons and other Regulatory Cytokines,John Wiley and Sons Publishers, Chapter 16, pps. 380-424, (1988).
Ealick et al., “Three-Dimensional Structure of Recombinant Human Interferon-γ”Science252:698-702 (1991.
Gray et al., “Expression of Human Immune Interferon cDNA inE. coliand Monkey Cells”Nature295:503-508 (Feb. 11, 1982).
Harrison et al., “Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis”Circulation29:84-98 (1964).
Hattori et al., “Role and Nuclear Factor KB in cytokine-induced nitric oxide and tetrahydrobiopterin synthesis in rat neonatal cardiac myocytes”J. Mol. Cell. Cardiol.29:1585-1592 (1997).
Hess et al., “Diastolic function and myocardial structure in patients with myocardial hypertrophy”Circulation63:360-371 (1981).
Inoue et al., “The Human Endothelin Family: Three Structurally and Pharmacologically Distinct Isopeptides Predicted by Three Separate Genes”Proc. Natl. Acad. Sci. USA86:2863-2867 (Apr. 1989).
Katz, “Heart Failure”Physiology of the Heart,Katz, A.M., New York:Raven Press, Chapter 25, pps. 638-668, (1992).
Katz, A., “Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart”Trends Cardiovasc. Med.5(1):37-44 (1995).
Kurzrock et al., “LIF: Not Just a Leukemia Inhibitory Factor”Endocrine Reviews12(3):208-217 (1991).
Lorell et al., “Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy”Circulation65:499-507 (1982).
Luss et al., “Characterization of inducible nitric oxide snythase expression in endotoxemic rat cardiacmyocytes in vivo and following cytokine exposure in vitro”J. Mol.&Cell. Cardiol.27:2015-2029 (1995).
Metcalf, “Leukemia Inhibitory Factor—A Puzzling Polyfunctional Regulator”Growth Factors7:169-173, (1992).
Morgan and Baker, “Cardiac Hypertrophy, Mechanical, Neural and Endocrine Dependence”Circulation83:13-25 (1991).
Pearlman et al., “Muscle fiber orientation and connective tissue content in the hypertrophied human heart”Lab. Invest46:158-164 (1982).
Pennica et al., “Expression Cloning of Cardiotrophin 1, a Cytokine That Induces Cardiac Myocyte Hypertrophy”Proceedings of the National Academy of Sciences, USA92:1142-1146 (Feb. 1995).
Pinsky et al., “The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β”J. Clin. Invest95:677-685, (1995).
Pollick, C., “Muscular subaortic stenosis, hemodynamic and clinical improvement after disopyramide”New England J. of Medicine307 (16):997-999 (1982).
Rossi et al., “Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy”Am. Heart J.124:700-709 (1992).
Schwarz et al., “Correlation between myocardial structure and diastolic properties of the heart in chronic aortic valve disease: effects of corrective surgery”Am. J. Cardiol.42: 895-903 (1978).
Shahi et al., “Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function”Lancet336:458-461 (1990).
Singh et al., “Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells”Journal of Biological Chemistry270:28471-28478 (1995).
Szlachcic et al., “Effects of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension”Am. J. Cardiol.63 : 198-201 (1989).
Taniguchi et al., “Human leukocyte and fibroblast interferons are structurally related”Nature285:547-549 (1980).
Thompson et al. “Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy”Br. Heart J.44:488-98 (1980).
Ungureanu-Longrois et al., “Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to γ-adrenergic agonists”Circ. Res.77:494-502 (1995).
Wigle et al., “Hypertrophic cardiomyopathy, clinical spectrum and treatment”Circulation92:1680-1692 (1995).
Yanagisawa and Masaki, “Molecular Biology and Biochemistry of the Endothelins”Trends Pharm. Sci.10:374-378 (Sep. 1989).
Adams et al., “Prostaglandin F2αstimulates hypertrophic growth of cultured neonatal rat ventricular myocytes”Journal of Biological Chemistry271 (2):1179-1186 (Jan. 12, 1996).
Anversa and Kajstura, “Ventricular myocytes are not terminally differentiated in the adult mammalian heart”Circulation Research83 (1):1-14 (Jul. 13, 1998).
Hansson and Holm, “Interferon-γ inhibits arterial stenosis after injury”Circulation84(3):1266-1272 (Sep. 1991).
Hansson et al., “Immune mechanisms in atherosclerosis”Arteriosclerosis9(5):567-578 (Sep.-Oct. 1989).
Pulkki K., “Cytokines and cardiomyocyte death”Annals of Medicine29 (4): 339-343 (Aug. 1997).
Shimokado et al., “Bidirection
Jin Hongkui
Lu Hsienwie
Paoni Nicholas F.
Yang Renhui
Dreger, Esq. Ginger R.
Genentech Inc.
Hasak, Esq. Janet E.
Heller Ehrman LLP
Landsman Robert S.
LandOfFree
Methods for treating cardiac hypertrophy by administering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cardiac hypertrophy by administering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cardiac hypertrophy by administering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530118